Literature DB >> 8752911

CD28 costimulation prevents cell death during primary T cell activation.

P J Noel1, L H Boise, J M Green, C B Thompson.   

Abstract

CD28 has been demonstrated to play an important role in augmenting T cell proliferation and effector function. Costimulation through CD28 has also been reported to enhance human T cell survival. in this report, we have further investigated the role of CD28 in regulating T cell survival by comparing the survival characteristics of T cells from wild-type and CD28-deficient mice. CD28 costimulation of anti-CD3-activated cells augmented the viability of T cells from wild-type but not from CD28-deficient mice. CTLA4Ig treatment reduced wild-type T cell viability to a level comparable with CD28-deficient T cells. The ability of CD28 to enhance survival during T cell activation correlated positively with its ability to up-regulate the protein product of the cell survival gene bcl-xL. No differences in the expression of either Bcl-2 or Fas were observed between wild-type and CD28-deficient T cells. The CD28-dependent enhancement of cell survival during in vitro activation was found to be independent of Fas expression, as CD28 costimulation enhanced T cell survival to comparable levels in both wild-type and lpr animals. Cell death in CD28-deficient animals and in wild-type animals treated with CTLA4Ig displayed the morphologic characteristics of apoptosis. Additionally, inhibitors of ICE proteases could reverse cell death induced by TCR engagement in the absence of CD28 costimulation. Thus, CD28 costimulation not only enhances the proliferative expansion of cells activated through the TCR but also increases the likelihood that individual cells survive during T cell activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752911

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

Review 1.  Controlling mature CD4+ T cell responses.

Authors:  M E Ozaki; S R Webb
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  Finally, CTLA4Ig graduates to the clinic.

Authors:  M H Sayegh
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

3.  Lack of costimulation by both sphingomyelinase and C2 ceramide in resting human T cells.

Authors:  D O'Byrne; D Sansom
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

Review 4.  PKC-θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.

Authors:  Myung-Ja Kwon; Ruiqing Wang; Jian Ma; Zuoming Sun
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-12       Impact factor: 2.895

Review 5.  CTLA-4 and tolerance: the biochemical point of view.

Authors:  Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 6.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

Review 7.  Studies of HIV-associated immune responses in lymphoid compartments.

Authors:  Susanna Grundström; Jan Andersson
Journal:  Curr HIV/AIDS Rep       Date:  2006-02       Impact factor: 5.071

8.  Activation or suppression of NFkappaB by HPK1 determines sensitivity to activation-induced cell death.

Authors:  Dirk Brenner; Alexander Golks; Friedemann Kiefer; Peter H Krammer; Rüdiger Arnold
Journal:  EMBO J       Date:  2005-12-08       Impact factor: 11.598

9.  Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis.

Authors:  M Hebbar; P Jeannin; G Magistrelli; P-Y Hatron; E Hachulla; B Devulder; J-Y Bonnefoy; Y Delneste
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

10.  A critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection.

Authors:  Santhakumar Manicassamy; Dengping Yin; Zheng Zhang; Luciana L Molinero; Marisa-Luisa Alegre; Zuoming Sun
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.